Signos Clinical Gaps & Limitations: What CGM-Based Weight Loss Programs Miss

The Evidence Gap: CGM for Weight Loss in Non-Diabetic Adults

Continuous glucose monitors were developed to help people with type 1 and type 2 diabetes manage glycemic variability. Signos repurposes this technology for a different population: people without diabetes who want to lose weight. The assumption is that real-time glucose feedback changes eating behavior enough to produce sustained fat loss. That assumption remains unproven at scale.

A 2021 systematic review in Nutrients examining CGM use in non-diabetic populations found that while users became more aware of postprandial glucose spikes, the data did not demonstrate consistent weight reduction [1]. The review included 11 studies, most with fewer than 50 participants and follow-up periods under 12 weeks. No study met the evidentiary bar of a large, pre-registered RCT with a primary weight-loss endpoint.

Compare this to the STEP-1 trial (N=1,961), which demonstrated that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo [2]. Or SURMOUNT-1 (N=2,539), where tirzepatide at the highest dose achieved 22.5% weight reduction at 72 weeks [3]. These are massive, double-blind, placebo-controlled trials published in the New England Journal of Medicine. Signos has nothing comparable.

The American Diabetes Association's 2024 Standards of Care explicitly recommend CGM for diabetes management but do not endorse CGM as a weight-loss intervention for metabolically healthy individuals [4]. That distinction matters.

What Signos Actually Does (and Doesn't Do)

Signos provides a CGM sensor (typically a Dexcom G7 or Abbott Libre), a smartphone app that scores meals based on glucose response, and AI-generated coaching suggestions. The program tells you which foods spike your glucose. It does not prescribe appetite-suppressing medications as part of its core model.

In late 2024, Signos added the option to prescribe metformin and GLP-1 receptor agonists through affiliated telehealth providers. This is a significant pivot. But the medications exist as add-ons to the CGM subscription, not as the primary therapeutic pathway. A person paying $299 per month for Signos who also needs semaglutide is paying for two separate services when the pharmacotherapy alone, with basic dietary counseling, may produce superior outcomes.

The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity recommends GLP-1 RAs as first-line pharmacotherapy for adults with BMI ≥30 (or ≥27 with comorbidities) [5]. The guideline does not mention CGM-based behavioral programs as a treatment for obesity. Not as primary therapy. Not as adjunctive therapy.

The Glucose-Centric Model: Physiologically Incomplete

Signos operates on a premise that controlling glucose spikes is the primary lever for fat loss. Glucose is one variable. Obesity is driven by energy balance, hormonal signaling (leptin, ghrelin, GLP-1, GIP, insulin), gut microbiome composition, central appetite regulation, genetics, sleep architecture, and psychological factors.

A 2022 paper in Cell Metabolism by Berry et al. demonstrated that postprandial glucose responses vary enormously between individuals eating identical meals and that glucose response alone explains only a fraction of metabolic health outcomes [6]. The PREDICT study (N=1,002) found that triglyceride responses to meals were actually more predictive of cardiometabolic risk than glucose responses in many participants.

Dr. Robert Lustig, professor emeritus of pediatric endocrinology at UCSF, has stated: "Glucose monitoring tells you what your pancreas is doing. It does not tell you what your fat cells are doing, what your hypothalamus is doing, or why you are hungry" [7].

Hunger regulation occurs primarily in the arcuate nucleus of the hypothalamus through leptin and ghrelin signaling. GLP-1 receptor agonists work precisely because they act on these central pathways, reducing appetite at the neurological level [8]. A CGM cannot modulate these pathways. It can only show you a number on a screen.

Cost-Effectiveness: The Math Doesn't Favor Signos

Signos charges between $199 and $399 per month depending on plan duration. A 12-month commitment at the lowest tier runs approximately $2,388 per year. For context, generic metformin ER 1,500 mg daily costs roughly $4 to $15 per month through most pharmacies. Compounded semaglutide, available through telehealth platforms like HealthRX, costs substantially less per month than Signos alone, and it comes with clinical evidence for 15%+ weight loss.

The cost question becomes sharper when you examine outcomes. If a person spends $2,388 on Signos for a year and achieves 3 to 5% body weight loss (a generous estimate given the absence of RCT data), the cost-per-percent of weight loss is roughly $477 to $796. If that same person spends a comparable amount on GLP-1 pharmacotherapy and achieves 15%, the cost-per-percent drops dramatically.

A 2023 cost-effectiveness analysis published in Annals of Internal Medicine found that semaglutide 2.4 mg met conventional willingness-to-pay thresholds for obesity treatment when accounting for reduced cardiovascular events, type 2 diabetes prevention, and improved quality-adjusted life years [9]. No equivalent analysis exists for CGM-based weight-loss programs because the efficacy data to model does not exist.

The Novelty Decay Problem

Behavioral research on self-monitoring technologies consistently shows a pattern: initial engagement is high, then drops. A 2020 study in the Journal of Medical Internet Research found that adherence to wearable health devices declines by approximately 50% within the first six months [10]. CGMs are subject to the same attrition curve.

Signos users frequently report on Reddit and Trustpilot that the first month feels revelatory. They discover that rice spikes their glucose more than they expected. They learn that walking after meals blunts spikes. By month three, the insights become repetitive. The sensor becomes an expensive accessory confirming what they already know.

This contrasts with pharmacotherapy, where the biological mechanism of action persists independent of user engagement. Semaglutide suppresses appetite whether or not the patient is actively thinking about their treatment. A CGM only works when the person changes behavior in response to the data, and behavioral change without pharmacological support has a well-documented recidivism rate exceeding 80% at five years in obesity treatment [11].

Signos vs. Evidence-Based Alternatives

The relevant comparison is not Signos versus doing nothing. It is Signos versus other interventions that cost the same or less and have actual trial data.

GLP-1 receptor agonist therapy. Semaglutide 2.4 mg (Wegovy) produced 14.9% body weight loss in STEP-1 [2]. Tirzepatide 15 mg (Zepbound) produced 22.5% in SURMOUNT-1 [3]. Both are FDA-approved for chronic weight management.

Metformin for weight maintenance. The Diabetes Prevention Program (DPP, N=3,234) showed that metformin 850 mg twice daily reduced progression to type 2 diabetes by 31% and produced modest weight loss of 2.1 kg over 2.8 years versus placebo [12]. Metformin costs under $15 per month.

Structured lifestyle intervention. The same DPP trial found that intensive lifestyle intervention (150 min/week exercise plus dietary counseling) reduced diabetes incidence by 58% and produced 5.6 kg average weight loss [12]. This required no CGM, no subscription, no sensor.

Phentermine-topiramate. The CONQUER trial (N=2,487) demonstrated 9.8% weight loss at 56 weeks with the highest dose combination [13]. Generic cost: approximately $30 to $80 per month.

Each of these alternatives has published Phase III data, FDA approval for a weight-related indication (or, in metformin's case, extensive off-label evidence), and a cost profile that is competitive with or lower than Signos.

Regulatory and Safety Considerations

The CGM hardware Signos uses (Dexcom G7 or Abbott FreeStyle Libre) carries FDA 510(k) clearance for glucose monitoring in diabetes. The FDA has not cleared or approved any CGM device with an indication for weight loss in non-diabetic individuals. Signos is not itself an FDA-regulated medical device; it is a software application that interprets data from a cleared device for an off-label purpose.

This is not illegal. Clinicians prescribe off-label regularly. But consumers should understand that "FDA-cleared CGM" does not mean "FDA-approved weight loss program." The distinction is not marketing nuance. It is a regulatory fact.

The FDA's 2023 guidance on clinical decision support software clarifies that software providing recommendations based on medical device data may itself require regulatory review depending on its intended use and risk profile [14]. Whether Signos's AI coaching falls under this umbrella remains an open question.

Sensor-related adverse events are generally minor (skin irritation, adhesive allergy, occasional inaccurate readings), but the psychological risk of orthorexic behavior from constant glucose monitoring has been flagged in eating disorder literature. A 2023 commentary in The Lancet Diabetes & Endocrinology raised concerns about CGM-driven dietary restriction patterns in non-diabetic users resembling disordered eating behaviors [15].

Who Might Genuinely Benefit from a CGM

CGM technology is not useless outside diabetes. Specific populations may derive value: individuals with reactive hypoglycemia, athletes optimizing fueling strategies, or people with prediabetes (HbA1c 5.7 to 6.4%) who want real-time feedback alongside a structured intervention. The American Association of Clinical Endocrinology (AACE) has acknowledged potential utility in prediabetes monitoring, though formal guideline recommendations remain limited to diabetes [16].

The issue is not CGMs as a technology. It is the Signos business model selling CGMs as a primary weight-loss solution at premium subscription pricing without the RCT evidence to support that claim. For a person with a BMI of 32 and no prediabetes, spending $300 per month on glucose data is difficult to justify when pharmacotherapy backed by trials enrolling thousands of participants is available.

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease [17]. That is a hard-endpoint cardiovascular outcome trial. No CGM-based weight loss company has data within several orders of magnitude of that evidence base.